Universitätsklinikum Regensburg
3 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 4 name spellings.
0
Ending by 2030
May 2033
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
No maintenance fee falls due on this company's record before Nov 17, 2027.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 7 of 7
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,714,286 | Diagnostic method for determining the presence and amount of human interleukin-3 in a sample using novel IL-3 antibodies In force · From the USPTO record | In force | From the USPTO record | |
| US 9,822,176 | IL-3 antibodies and their use in diagnosis and treatment of diseases or malfunctions associated with elevated levels of IL-3 In force · From the USPTO record | In force | From the USPTO record | |
| US 9,938,343 | Diagnostic method for determining the presence and amount of human interleukin-3 in a sample using novel IL-3 antibodies In force · From the USPTO record | In force | From the USPTO record | |
| US 10,768,167 | Plasma membrane citrate transporter for use in the diagnosis and treatment of cancer In force · From the USPTO record | In force | From the USPTO record | |
| US 12,247,973 | Plasma membrane citrate transporter for use in the diagnosis and treatment of cancer In force · From the USPTO record | In force | From the USPTO record | |
| US 11,078,266 | Anti-Human IL-3 Antibodies, Their Use in Treatment of a Disease or Malfunction Associated with Elevated Expression or Levels of IL-3, and Their Use in a Method to Detect Human IL-3 In force · High confidence | In force | High confidence | |
| US 12,338,280 | Antibodies Targeting IL3 In force · High confidence | In force | High confidence |
Also on record, not counted in the 7: 3 patents in force now held by others · 1 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 pending · 1 abandoned · 1 no status recorded